Suppr超能文献

心血管试验中复合终点使用的问题:随机对照试验的系统评价

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

作者信息

Ferreira-González Ignacio, Busse Jason W, Heels-Ansdell Diane, Montori Victor M, Akl Elie A, Bryant Dianne M, Alonso-Coello Pablo, Alonso Jordi, Worster Andrew, Upadhye Suneel, Jaeschke Roman, Schünemann Holger J, Permanyer-Miralda Gaietà, Pacheco-Huergo Valeria, Domingo-Salvany Antònia, Wu Ping, Mills Edward J, Guyatt Gordon H

机构信息

Departament de Medicina, Universitat Autònoma de Barcelona, and Hospital Vall d'Hebron, Barcelona 08035, Spain.

出版信息

BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2.

Abstract

OBJECTIVE

To explore the extent to which components of composite end points in randomised controlled trials vary in importance to patients, the frequency of events in the more and less important components, and the extent of variability in the relative risk reductions across components.

DESIGN

Systematic review of randomised controlled trials.

DATA SOURCES

Cardiovascular randomised controlled trials published in the Lancet, Annals of Internal Medicine, Circulation, European Heart Journal, JAMA, and New England Journal of Medicine, from 1 January 2002 to 30 June 2003. Component end points of composite end points were categorised according to importance to patients as fatal, critical, major, moderate, or minor.

RESULTS

Of 114 identified randomised controlled trials that included a composite end point of importance to patients, 68% (n=77) reported complete component data for the primary composite end point; almost all (98%; n=112) primary composite end points included a fatal end point. Of 84 composite end points for which component data were available, 54% (n=45) showed large or moderate gradients in both importance to patients and magnitude of effect across components. When analysed by categories of importance to patients, the most important components were associated with lower event rates in the control group (medians of 3.3-3.7% for fatal, critical, and major outcomes; 12.3% for moderate outcomes; and 8.0% for minor outcomes). Components of greater importance to patients were associated with smaller treatment effects than less important ones (relative risk reduction of 8% for death and 33% for components of minor importance to patients).

CONCLUSION

The use of composite end points in cardiovascular trials is frequently complicated by large gradients in importance to patients and in magnitude of the effect of treatment across component end points. Higher event rates and larger treatment effects associated with less important components may result in misleading impressions of the impact of treatment.

摘要

目的

探讨随机对照试验中复合终点的各个组成部分对患者的重要性差异程度、重要性较高和较低的组成部分中的事件发生频率,以及各组成部分相对风险降低的变异性程度。

设计

对随机对照试验进行系统评价。

数据来源

2002年1月1日至2003年6月30日发表在《柳叶刀》《内科学年鉴》《循环》《欧洲心脏杂志》《美国医学会杂志》和《新英格兰医学杂志》上的心血管随机对照试验。复合终点的组成终点根据对患者的重要性分为致命、危急、主要、中度或次要。

结果

在114项确定的包含对患者重要的复合终点的随机对照试验中,68%(n = 77)报告了主要复合终点的完整组成数据;几乎所有(98%;n = 112)主要复合终点都包含一个致命终点。在84个有组成数据的复合终点中,54%(n = 45)在对患者的重要性和各组成部分的效应大小方面显示出大或中等程度的梯度。按对患者的重要性类别分析时,最重要的组成部分与对照组中较低的事件发生率相关(致命、危急和主要结局的中位数为3.3 - 3.7%;中度结局为12.3%;次要结局为8.0%)。对患者更重要的组成部分与比不太重要的组成部分更小的治疗效果相关(死亡的相对风险降低8%,对患者不太重要的组成部分为33%)。

结论

在心血管试验中使用复合终点常常因各组成终点对患者的重要性以及治疗效果大小存在较大梯度而变得复杂。与不太重要的组成部分相关的较高事件发生率和较大治疗效果可能会导致对治疗影响产生误导性印象。

相似文献

1
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.
BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2.
3
Home treatment for mental health problems: a systematic review.
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
4
Acupuncture for depression.
Cochrane Database Syst Rev. 2018 Mar 4;3(3):CD004046. doi: 10.1002/14651858.CD004046.pub4.
5
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Direct composite resin fillings versus amalgam fillings for permanent posterior teeth.
Cochrane Database Syst Rev. 2021 Aug 13;8(8):CD005620. doi: 10.1002/14651858.CD005620.pub3.
7
Sertindole for schizophrenia.
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
8
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5.
10
Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care.
Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD010130. doi: 10.1002/14651858.CD010130.pub3.

引用本文的文献

1
Expanding the use and interpretation of patient-centric cardiovascular clinical trial endpoints.
J Clin Transl Sci. 2025 Jul 3;9(1):e151. doi: 10.1017/cts.2025.10054. eCollection 2025.
2
Post-COVID-19 cardiovascular disease risk in kidney transplant recipients.
Am J Transplant. 2025 Jul 15. doi: 10.1016/j.ajt.2025.07.2462.
4
Transparency in Science Reporting: A Call to Researchers and Publishers.
Cureus. 2025 Feb 23;17(2):e79493. doi: 10.7759/cureus.79493. eCollection 2025 Feb.
5
Severe maternal morbidity in the high income setting: a systematic review of composite definitions.
EClinicalMedicine. 2025 Feb 13;81:103105. doi: 10.1016/j.eclinm.2025.103105. eCollection 2025 Mar.
7
Composite end points and competing risks analysis.
Interdiscip Cardiovasc Thorac Surg. 2024 Jul 3;39(1). doi: 10.1093/icvts/ivae126.
8
Assessment of Nonfatal Bleeding Events as a Surrogate for Mortality in Coronary Artery Disease.
JACC Adv. 2023 Feb 20;2(3):100276. doi: 10.1016/j.jacadv.2023.100276. eCollection 2023 May.
9
Are Bleeding Events Valid as a Surrogate Endpoint for Mortality in Cardiovascular Clinical Trials?
JACC Adv. 2023 May 26;2(3):100335. doi: 10.1016/j.jacadv.2023.100335. eCollection 2023 May.
10
Composite to Clarity: Shifting From Combined to Individual Endpoints in Meta-Analyses of Cardiovascular Outcome Trials.
JACC Adv. 2023 Aug 6;2(7):100548. doi: 10.1016/j.jacadv.2023.100548. eCollection 2023 Sep.

本文引用的文献

1
Key issues in end point selection for heart failure trials: composite end points.
J Card Fail. 2005 Oct;11(8):567-75. doi: 10.1016/j.cardfail.2005.08.350.
2
Validity of composite end points in clinical trials.
BMJ. 2005 Mar 12;330(7491):594-6. doi: 10.1136/bmj.330.7491.594.
4
Measuring inconsistency in meta-analyses.
BMJ. 2003 Sep 6;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
5
Composite outcomes in randomized trials: greater precision but with greater uncertainty?
JAMA. 2003 May 21;289(19):2554-9. doi: 10.1001/jama.289.19.2554.
6
Combined endpoints: can we use them?
Stat Med. 2002 Oct 15;21(19):2959-70. doi: 10.1002/sim.1300.
7
Lessons learned from recent cardiovascular clinical trials: Part I.
Circulation. 2002 Aug 6;106(6):746-51. doi: 10.1161/01.cir.0000023219.51483.66.
8
Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts.
N Engl J Med. 2002 Apr 18;346(16):1194-9. doi: 10.1056/NEJMoa012579.
10
One thousand health-related quality-of-life estimates.
Med Care. 2000 Jun;38(6):583-637. doi: 10.1097/00005650-200006000-00004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验